GlassScriptPhysician profile
Whitney Primeau
NPI 1639836174
$1,229.72
in general payments reported to CMS, 2019-2025
18 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $34.76 · 2024: $735 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $700.21 | 2023-2025 | |
| Celgene Corporation | $62.14 | 2024 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $58.28 | 2024 | Rexulti |
| Neurocrine Biosciences, INC. | $56.90 | 2024 | Ingrezza |
| Lundbeck LLC | $41.00 | 2024-2025 | Rexulti, Vyepti |
| Lilly USA, LLC | $39.53 | 2024-2025 | Kisunla, Reyvow, Emgality |
| Novartis Pharmaceuticals Corporation | $38.09 | 2024 | |
| Ucb, INC. | $36.92 | 2024 | Briviact |
| Genentech USA, INC. | $23.71 | 2025 | Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $23.64 | 2024 | Ultomiris |
| Tanabe Pharma America, INC. | $23.34 | 2024 | |
| Eisai INC. | $22.54 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.84 | 2024 | Rexulti |
| Livanova USA, INC. | $18.38 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Hospira, INC. | $18.05 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.62 | 2025 | |
| Argenx US, INC. | $15.81 | 2024 | Vyvgart Hytrulo |
| Acorda Therapeutics, INC | $13.72 | 2024 | Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Primeau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.